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Diagnostic tools for a new inborn error of metabolism
A n d  read S c h u lze , MD, T h o m a s  Hedd, MD, R o n  Weverd, MD, E r ta n  M a y a te p e k ,  MD\ P e te r  Bachert, PhD, 
B a r t  A ia red ca u , DSc, A i ic h a e l  V  K n o p p , MD, P e ter  P  D e  D e y n , MD, PhD, H a n d  J. Bremer, ¿MD, a n d  
D i e t z  R a t in g ,  MD
Hepatic guanidinoacetate me thy I tr an s fer as e deficiency induces a deficiency of crea­
tine/p hosphocreatine in muscle and brain and an accumulation of guanidinoacetic acid 
(GAA), the precursor of creatine. We describe a patient with this defect, a 4-year-old 
girl with a dystonic-dyskinetic syndrome in addition to developmental delay and thera­
py-resistant epilepsy. Several methods were used in the diagnosis of the disease: (1) the 
creatinine excretion in 24-hour urine was significantly lowered, whereas the creatinine 
concentration in plasma and in randomly collected urine was not strikingly different 
from control values; (2) the Sakaguchi staining reaction of guanidino compounds in 
random urine samples indicated an enhanced GAA excretion; (3) GAA excretion mea­
sured quantitatively by guanidino compound analysis using an amino acid analyzer was 
markedly elevated in random urine samples; (4) in vivo magnetic resonance spec­
troscopy (MRS) revealed a strong depletion of creatine and an accumulation of GAA 
in brain; (5) in vivo phosphorus 31 M RS showed a strong decrease of the phospliocre- 
atine resonance and a resonance identified as guanidino acetate phosphate; and (6) in 
vitro 1H M RS showed an absence of creatine and creatinine resonances in cere­
brospinal fluid and the occurrence of GAA in urine. For early detection of this disease, 
we recommend the Sakaguchi staining reaction of urine from patients with dystonic- 
dyskinetic syndrome, seizures, and psychomotor retardation. Positive results should re­
sult in further investigations including quantitative guanidino compound analysis and 
both in vivo and in vitro M RS. Although epilepsy was not affected by orally adminis­
tered creatine (400 to 500 mg/kg per day), this treatment resulted in clinical improve­
ment and an increase of creatine in cerebrospinal fluid and brain tissue. (J Pediatr
1997;131:626-31)
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Creatine deficiency syndrome is a recently 
discovered inborn error of metabolism.1 The 
disturbed biosynthesis of creatine is caused 
by deficiency of hepatic guanidinoacetate 
methyltransferase (iS'-adenosylmethionine: 
guanidinoacetate //-methyltransferase [EC
2.1.1.2]). Human GAMT complementary 
DNA has meanwhile been cloned and its se­
quence analyzed.  ^Guanidinoacetic acid, the 
immediate precursor of creatine, is formed 
in human liver, renal cortex, and pan­
creas.3’^  It is transported to muscle, brain, 
and other tissues by a creatine transporter, a 
member of the sodium-dependent plasma
membrane transporter family,5“7 Because of 
the importance of the creatine/phosphocrea- 
tine pool for the storage and transmission of 
phosphate-bound energy, it is essential to 
maintain intracellular creatine homeostasis. 
Both creatine and phosphocreatine undergo 
a first-order nonenzymatic cyclization to 
creatinine. An amount of creatine equal to 
the amount of the daily creatinine excretion 
(~2 gm in an adult man) must be replaced 
by exogenous sources of creatine in foods or 
by endogenous synthesis.
See editorial, p. 5 10.
^ w w » — ....... .
In the index patient with creatine de­
ficiency syndrome, in vivo magnetic reso­
nance spectroscopy revealed an almost 
complete deficiency of creatine in brain 
and proved to be the key to the discoveiy 
of this disease. Oral creatine substitution 
led to clinical improvement in this pa-
CSF Cerebrospinal fluid
GAA Guanidinoacetic acid
GAMT Guanidinoacetate methyltransferase
MRS Magnetic resonance spectroscopy
TLC Thin-layer chromatography
We present a second patient with this 
disease, which was primarily diagnosed 
by in vivo MRS. The clinical course of 
both patients after more than 1 year of 
creatine substitution suggests the necessity 
of early treatment. Therefore the devel­
opment of simple and inexpensive diag­
nostic techniques for early detection is re­
warding.
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Case R e p o r t  Treatment with creatine monohydrate
was started with a dosage of 400 mg’/kg 
per day, which increased 3 months later to 
The female patient was born after an 500 mg/kg per day. During the first 2
uncomplicated pregnancy and labor at 
term to healthy Kurdish parents (first
months of treatment we noticed improve­
ment in mental and motor functions, 
cousins). Five siblings are healthy. At 6 However, it soon became obvious that the 
months of age, retarded psychomotor de- patient s psychomotor status was deter-
velopmenl was noticed. At 15 months, she 
was unable to sit and crawl. At 2 V2 years
mined predominantly by the course of the 
epilepsy. After a decrease in the frequency
of age, she was able to pull up for sup- of absences and drop attacks, the girl be-
ported standing and walking, but there came more alert, started to play, and tried
was no speech. At 3 years of age a loss of to pull up for standing and supported
acquired functions was reported. Within a walking. However, epilepsy proved to be 
few months she was no longer able to sit, 
to crawl, or to pull up for standing. She
impression that the dystonic-dyskinetic 
syndrome abated with creatine supple­
mentation.
drug resistant, and the child went many 
times and sometimes for weeks into minor 
lost social contact, stopped playing, and motor status with loss of mental and 
appeared sedated and dull. At 14 months motor function. Nevertheless, it was our 
of age, she had a prolonged febrile con­
vulsion. Since that time she has had 
epilepsy with rare grand mal seizures, fre­
quent drop attacks, and absences.
Antiepileptic drug therapy including phé­
nobarbital, valproate, ethosuximide, 
vigabatrin, carbamazepine, lamotrigine, 
and corticoids showed no benefit.
We saw the girl for the first time at the 
age of 3 years 8 months. She had micro-
M e t h o d s
Biochemical Determination, o f  
Creatinine
Creatinine measurements in blood and
cephaly and wasting, was unable to sit up urine samples were performed biochemi-
or to pull up for standing or walking, and cally by means of a modified Jaflfe method. ^  
she could hardly grasp. She exhibited an
extrapyramidal syndrome with dyskinet- Salzacfllchi Reaction
ic-dystonic involuntary movements in 
which, except during sleep, the upper ex­
tremities were more involved than the
Urinaiy guanidino compounds were de­
tected after their thin-layer chromatogra­
phy separation using the Sakaguchi reac-
lower ones. Moreover, she had nonepilep- tion,11,12 In this simple screening method, 
Lie myoclonic jerks, and she had pyrami- staining of monosubstituted guanidines 
dal signs characterized by increased mus­
cle tone of the lower limbs and increased
such as arginine, argininosuccinic acid, 
homoarginine, or GAA shows clearly an 
increased excretion of GAA.deep tendon reflexes. Cranial magnetic 
resonance imaging revealed marked bilat­
eral myelination delay of white matter, a Determination o f Guanidino
large cisterna magna, and multiple der- C o m p o u n d s
moids. An electroencephalogram showed The concentration of the guanidino
bilaterally synchronous and diffuse slow compounds was determined with a model 
spike waves, not significantly influenced LC 5001 amino acid analyzer (Biotronik,
by progression of disease nor by 
antiepileptic drug therapy. Acoustic 
evoked potentials and motor nerve con­
duction velocity were normal. Laboratory 
investigations revealed no striking abnor­
malities except mild hyperammonemia
(65 to 145 f-tmol/L) and intermittently ele­
vated lactate concentrations in blood and
CSF (1,0 to 3.7 mmol/L and 1.2 to 2.6
m mol/L, resp e c tive ly).
Maintal, Germany) adapted for guanidino 
compound determination, The guanidino 
compounds were separated over a cation 
exchange column as described elsewhere 
in detail13
In Vivo 1H  and Phojphonu 31
MRS
In vivo lH and 31P MRS examinations 
of the brain were performed at Bq -  1.5T
in a whole-body magnetic resonance sys­
tem (Magnetom 63/84 SP 4000; Siemens, 
Erlangen, Germany). Spectra were ac­
quired before and during oral therapy 
with L-arginine and creatine monohy­
drate. Localized 63 M H z-lIi MRS spec­
tra were obtained in single-voxel tech­
nique with the stimulated echo pulse 
sequence.1** The voxel was placed in the 
basal ganglia (voxel size = 8 cm3). 
Measurement parameters in the first and 
second examination were TR = 6000 msec 
(repetition time), T E = 20 msec (echo 
time), T ^  = 30 msec (middle interval), 
and T r -  1500 msec, T^ = 50 msec, T ^  =
30 msec in the third examination number 
of experiments (NEX)  -  170 excitations). 
Nonlocalized 3IP M RS spectra were ac­
quired with a one-pulse sequence (TR «
2000 ms, N E X  = 200) with a crossed
Helmholtz head coil.
H igh-resolution In Vitro M RS
In vitro MRS of CSF and urine was 
carried out as recently described-15,16 
Depending on the body fluid, analyzed 
samples were directly lyophilized (urine) 
or first filtered with a 10 kd filter (CSF). 
Samples were dissolved in deuterium oxide 
with trimethylsilyl 2,2,3,3-tetradeuteropro- 
pionic acid as the internal standard. Care 
was taken to standardize the pH  of the 
samples (2.50 ± 0.10). Subsequently a 600 
MHz 'H MRS spectrum was obtained at 
298 K with a 60-degree radiofrequency 
pulse and Tj^=12 seconds.
D eterm ination  o f E nzym e  
A ctivity
The GAMT activity of liver tissue was 
determined by measuring the transfer of 
[methyl-3 H] groups from iS-ade nosy I me­
thionine to GAA.17
R e s u l t s
C reatinine in P lasm a and  
Urine (Jaffé M ethod)
Plasma creatinine was found to be con­
stantly in the lower normal range (18 
jLtmol/L; normal range, 18 to 90). The cre­
atinine concentration in random urine 
samples was not suspect and ranged from
low to normal values (1300 to 5400 
|Hmo]/L; normal range, 1800 to 4400). In
Sch u lze  et a l .
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Fig. 1. Localized in vivo 'H MRS of the brain of the patient with creatine deficiency syndrome at B0 = 
l.5TThe voxel (8 cm3) was placed in the basal ganglia. Spectra (63 MHz Larmor frequency) were ac­
quired, A, before therapy, B, during oral treatment with L-arginine (300 mg/kg per day), and C, during 
creatine monohydrate supplementation (400 mg/kg per day). Ino, Inositols; tCho,choline-containing com­
pounds; tO, total creatine (mainly creatine and phosphocreatine); NAA, N-<7cety'/-L-aspartate.
contrast, the creatinine excretion in 24- 
hour urine samples was diminished (38 to 
AS ¡lmol/kg per day; normal range, 8« 
132). During treatment with creatine, the 
plasma creatinine concentration increased 
(27 to 35 JUmoI/L) and the daily creatinine 
excretion became normal (131 JLlmol/l-cg 
per day).
Sakaguchi Reaction
GAMT deficiency leads to an increase 
in GAA in body fluids and tissues. At the 
time of diagnosis we investigated, by 
means of the Sakaguchi staining reaction 
on TLC plates, the urine samples of the 
two patients known at that time to have 
creatine deficiency syndrome. There was
repeatedly a positively stained spot with 
the chromatographic running behavior of 
GAA (fading orange to red) on TLC 
plates, with simultaneous negative control 
results. The detection limit for GAA by 
this method was estimated to be 2.5 
mmol/L.
Quantitative Guanidino 
Compound Ana tydid
The urinary excretion levels of GAA 
determined by ion exchange chromatog­
raphy were markedly increased (361 to 
509 jimol/mmol creatinine; normal range, 
28 to 96), whereas the creatine excretion 
was decreased (17.6 to 29.3 jimol/mmol 
creatinine; normal range, 45 to 362 ).
Furthermore, a small increase in urinary 
levels of guanidinosuccinic acid, y-guani- 
dinobutyric acid, and guanidine was
found (17.0 to 19.1, 4.9 to 7.1, and 5,3 to
5.6 |Llmol/mmol creatinine, respectively; 
normal ranges, 2.8 to 11.3, 0.6 to 3.4, and 
1,1 to 2.8, respectively). Creatine treat­
ment caused an excessive increase in cre­
atine excretion without normalization of
GAA in urine (10,753 and 617
jlmol/mmol creatinine, respectively).
In  Vivo and 31 P  MRS o f the
Brain
The patients localized *H MRS spec­
trum (Fig. 1, A), obtained before treat­
ment, shows a strongly reduced signal of 
total creatine (mainly creatine and phos­
phocreatine) in comparison with spectra 
acquired from the brain tissue of healthy 
volunteers. Besides the resonances ol 
Af-acetyl-L-aspartate, choline-containing 
compounds, and inositols, peaks of lower 
intensity are found at 2.1 to 2.6 ppm. The 
resonance at 6 = 3.8 ppm is assigned to 
GAA.18 No lactate signal was seen.
The ,<51P MRS spectra (Fig, 2) show
strong signals of phosphodiesters and 
phosphomonoesters. Evaluation19 of the 
chemical shift difference of phosphocrea­
tine (8 = 0.0 ppm) and inorganic phos­
phate (8 = 5.1 ppm) yields an apparent in­
tracellular pH of 7.24. For comparison, 
mean pH is 7.07 ± 0.02 in healthy human 
brain tissue. A well-resolved peak was 
found at 8 = —0*4 ppm, close to and 
stronger than the resonance of phospho­
creatine at 8 = 0.0 ppm (Fig. 2, A ). 
Concomitant with the findings in the *H
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Fig. 2. In vivo 31P MRS of the brain of the patient with creatine deficiency syndrome at B0 = 1.5T. 
Nonlocalized phosphorus magnetic resonance spectra (26 MHz Larmor frequency) were acquired, A , be­
fore therapy and, B, during creatine monohydrate supplementation (400 mg/kg per day). PCr% 
Phosphocreatine; CAP, gu an id i noacetate phosphate; PME, phosphomonoester; PD£, phosphodi ester; Pi, inor­
ganic phosphate; NTP, nucleoside 5 '-triphosphate,
MRS spectra, this intense signal was as­
signed to gu an id i noacetate phosphate on 
the basis of its chemical shift.1® The un­
usual low intensity of the phosphocreatine 
signal before treatment agrees with the re­
duced total creatine resonance in the *H
MRS spectra.
After oral substitution of L-arginine 
(300 mg/kg per day for 1 month); no sig­
nificant changes were seen in the 1H MRS 
spectra (Fig. 1, B). ‘^ P  MRS could not be 
performed at this stage because the patient 
was too agitated. In contrast, oral substitu­
tion of creatine produced a significant in­
crease of creatine and phosphocreatine 
signal intensities in (Fig. 1, C) and 31P 
(Fig.2, B) spectra. In the MRS spec­
trum a decrease in GAA and an increase in 
choline-containing compound signal in­
tensities were seen. At this stage the 31P 
MRS resonance of guanidinoacetate 
phosphate could no longer be resolved. A 
relative decrease in phosphodiesters and, 
particularly, in phosphomonoesters sig­
nals was found. Intensity, line width, and 
chemical shift of the inorganic phosphate 
resonance were reduced (5 = 4.8 ppm); the 
calculated pH was approximately 7.07 
(ApH = -0 .17) (i.e., in the normal range) 
after administration of creatine. The sig- 
nal-to-noise ratio of the three nucleoside 
S'-triphosphate resonances was lower 
than that of the spectrum in Fig. 2, A.
In Vitro 1H  MRS of CSF,
Pladnia, and Urine (Table)
In CSF the creatine resonance was 
lacking completely, and the creatinine res­
onance was strongly reduced. Resonances 
of these metabolites were always present 
in CSF samples of 60 patients with other 
neurologic diseases.15 The concentrations 
of creatine and creatinine in CSF clearly 
distinguish control values and our patient. 
GAA could not be quantified reliably in 
CSF with in vitro *H MRS. Fig. 3 shows 
the spectrum of the patient s CSF (Fig. 3, 
A) compared with a normal CSF spec­
trum (Fig. 3, 3 ) .
In random urine samples, creatine was 
not detectable, but the reference range for 
urinary creatine excretion is broad, rang­
ing from veiy low to high values. In con­
trast, the creatinine values were normal in 
comparison with values determined by 
conventional techniques.
Treatment with creatine led to an exces­
sive increase in creatine concentrations in 
urine and plasma but only to a rise into the 
normal range in CSF. In contrast to the 
creatine excess, creatinine increased only 
within the normal range in all investigated 
body fluids. The GAA excretion was 
found to be elevated during both arginine 
and creatine treatment. Unfortunately, 
quantitative values before treatment could 
not be obtained with this method because 
of an interfering metabolite.
Investigation o f L iver Tiddue
A needle biopsy of liver revealed a 
slight centrilobular fatty liver and cirrho­
sis. The activity of GAMT was almost 
completely deficient (0.5 nmol/hr per 
gram liver; control range, 33.8 to 38.8; n =
6), confirming the diagnosis of hepatic 
GAMT deficiency8
D is c u s s io n
The most predominant clinical feature 
of the creatine deficiency syndrome seems 
to be extrapyramidal symptoms mainly 
characterized by dy^kinetic-clystonic in­
voluntary movements. The progressive 
loss of motor and mental functions points 
to the neu rodegenerative nature of the 
disease. The course of the disease in our 
patient was complicated by therapy-resis­
tant epilepsy with myoclonic and astatic 
seizures, as well as grand mal convulsions.
Therapy for the creatine deficiency syn­
drome consists of the oral supplementa-
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Fig. 3. A, In vitro 600 MHz lH MRS of cerebrospinal fluid of the patient with creatine deficiency syndrome, in comparison with, B, a normal CSF spectrum,
Treatment
tion of creatine. We noticed a striking Table. M e ta b o lite  p ro file  in M R S  o f  random  u rine  sam ples and of p lasm a and cere- 
clinical improvement within the first 2 b ro sp ina l fluid 
months of treatment but no further 
progress during“ the following 18 months.
The epilepsy, which seemed to be respon­
sible for the psyciiomotor and mental sta­
tus, could not be influenced. This might 
be explained by an incomplete restoration 
of intracellular creatine homeostasis or by 
tlie neurotoxic effects o f GAA, which  
could not be completely removed by crea­
tine substitution. Moreover, the worse 
clinical course may be a result of in­
tractable epilepsy and perhaps may be in­
dependent of cerebral creatine/GAA.
The deficient GAMT activity in our pa­
tient is based on a homozygous 327 G—>A 
mutation,8 The GAMT deficiency is bio­
chemically characterized by lack of crea­
tine and its derivatives and by tbe accu­
mulation of GAA. Thus the finding of 
lowered creatine and its derivatives and 
the accumulation of GAA both facilitate 
the diagnosis of this disease. Diagnosis of
the disease in the presently known two phocreatine levels and unusual reso- disorders. As clearly demonstrated in our
Metabolite 
Body fluid Without Arginine Creatine
Control values* 
(7C= 15)
Creatine
Urine <5 <5 12000 30-1140
Plasma -- — 496 100-264
CSF <2 <2 46 25-70
Creatinine
Urine 4500 3200 1800 730-14,960
Plasma — 36 25-100
CSF <2 <2 92 20-100
GAA
Urine IFM 1000 520 <961'
M easurements: urine, micromoles per millimole of creatinine; plasma and CSF, micromoles per liter. 
IF/PI, Interfering metabolite.
"Reference data for creatine and creatinine w ere derived from a group of 15 children (ages 1 to 5 years) 
and  were measured with M RS.
^Reference data for GAA were derived from a group o f 12 children and were measured by ion exchange 
chromatography.
patients was primarily based on in vivo 
MRS of the brain, which demonstrated
nances assigned to GAA and guanidi- 
noacetate phosphate. In vitro MRS of
patient  ^ this method proved to be useful 
for the diagnosis of creatine deficiency
the diagnostic utility of MRS. and 3iP CSF is still under investigation as a gen- syndrome. In our patients CSF samples,
spectra revealed low creatine and phos- eral screening method in neurometabolic creatine and creatinine concentrations as
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measured by in vitro MRS were found 
to be below the detection limit. This find­
ing seems to be pathognomonic, suggest­
ing that analysis of creatine and creatinine 
in CSF may be a reliable diagnostic 
method for the disease. In the diagnostic 
study, we recommend the Sakaguchi re­
action in randomly collected urine after 
TLC separation as a simple screening 
method and, in addition, the measurement 
of creatinine in 24-hour urine samples. 
Subsequently further diagnostic study 
should include quantitative determination 
of guanidino compounds in 24-hour urine 
samples. As clearly demonstrated in our 
patient, in vitro lH MRS and in vivo 
lj_j/31p JY[RS, which can be added to rou­
tine magnetic resonance imaging, are use­
ful diagnostic tools and should, whenever 
possible, at least be performed in all pa­
tients with neurologic symptoms such as 
extrapyramidal signs, seizures, and psy­
chomotor retardation.
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